Tesamorelin (HPLC-Verified / Batch COA)⁠

Tesamorelin Research Reagent | Stabilized GHRH Polypeptide Analogue

Tesamorelin is a synthetic peptide containing all 44 amino acids of native human Growth Hormone-Releasing Hormone (GHRH), uniquely modified at its N-terminus with an attached trans-3-hexenoic acid group. Positioned prominently within UK and global preclinical endocrine frameworks, this structural adjustment dramatically restricts immediate cleavage by dipeptidyl peptidase-4 (DPP-4), expanding its analytical lifespan compared to native GHRH without lowering its natural receptor target affinity.

By acting as a stabilized GHRH receptor agonist, Tesamorelin selectively stimulates somatotrophic cells in the anterior pituitary. This drives the natural, pulsatile release of endogenous growth hormone and downstream insulin-like growth factor-1 (IGF-1). In laboratory evaluation models, its localized action provides an ideal baseline for examining specific lipid metabolism pathways—particularly the selective oxidation of deep visceral adipose tissue over subcutaneous depots.

Batch-Specific HPLC Analysis & Validation

To secure the strict reproducibility required for advanced cellular bioassays, this range undergoes rigorous analytical control verification:

• HPLC Spectral Characterization: Every compound batch is subjected to High-Performance Liquid Chromatography to verify chemical purity parameters equal or exceed 99.0%.
• Mass Spectrometry Authentication: Verifies exact molecular weight metrics, guaranteeing the presence of the full 44-amino acid sequence alongside its N-terminal trans-3-hexenoic acid modification.
• Batch Certificate of Analysis (COA): Accessible batch documentation ensures that baseline quantitative observations are protected against unintended chemical variability.

Experimental Research Context & Mechanisms

During preclinical investigation and laboratory mapping, Tesamorelin is primarily used to analyze:

• Visceral Lipolysis Pathways: Mapping how growth hormone spikes downregulate lipogenic enzymes, studying the selective mobilization of visceral fat over subcutaneous deposits.
• Glucose Homeostasis Variations: Studying how sustained GHRH signaling impacts insulin sensitivity profiles and systemic carbohydrate metabolism over longer trial periods.
• Neuroprotective Signaling Loops: Investigating emerging models that track GHRH-mediated somatotrophic feedback within cortical regions to map cognitive and tissue maintenance parameters.

Laboratory Storage & Handling Protocols

To ensure maximum chemical longevity and protect the 44-amino acid structure from premature fragmentation, follow these handling procedures:

• Lyophilized Protection: Unreconstituted vials should be stored inside a laboratory freezer at -20°C for long-term storage. Keep environments fully desiccated and shielded from direct UV exposure.
• Reconstitution Calibration: Allow the vacuum-sealed vial to balance completely with ambient room temperature before introducing the bacteriostatic solvent. This prevents thermal shock from degrading the complex peptide matrix.
• Post-Solvent Management: Once fluid is added, store the liquid solution strictly between 2°C and 6°C. Never shake or agitate the vial sharply; mix using a gentle, slow circular swirling pattern. Complete all experimental models within 10 to 14 days of fluid introduction.